Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 986 GBX 0.94% Market Closed
Market Cap: 8.6B GBX
Have any thoughts about
Smith & Nephew PLC?
Write Note

Operating Margin
Smith & Nephew PLC

12.3%
Current
13%
Average
4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.3%
=
Operating Profit
696m
/
Revenue
5.6B

Operating Margin Across Competitors

Country UK
Market Cap 8.6B GBP
Operating Margin
12%
Country US
Market Cap 199B USD
Operating Margin
17%
Country US
Market Cap 191.3B USD
Operating Margin
26%
Country US
Market Cap 141.3B USD
Operating Margin
22%
Country US
Market Cap 134.2B USD
Operating Margin
18%
Country IE
Market Cap 104.6B USD
Operating Margin
19%
Country US
Market Cap 65.6B USD
Operating Margin
14%
Country DE
Market Cap 58.1B EUR
Operating Margin
12%
Country US
Market Cap 44.5B USD
Operating Margin
28%
Country CN
Market Cap 310B CNY
Operating Margin
36%
Country US
Market Cap 36.3B USD
Operating Margin
13%
No Stocks Found

Smith & Nephew PLC
Glance View

Market Cap
8.6B GBX
Industry
Health Care

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 468.78 GBX
Undervaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.3%
=
Operating Profit
696m
/
Revenue
5.6B
What is the Operating Margin of Smith & Nephew PLC?

Based on Smith & Nephew PLC's most recent financial statements, the company has Operating Margin of 12.3%.